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Positron emission tomographya b s t r a c t
Assessment with 18F-ﬂuorodeoxy glucose (FDG)epositron emission tomography (PET) before hematopoi-
etic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with
chemotherapy-sensitive noneHodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center
of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-
HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We
analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n ¼ 104) was
more common than large cell (n ¼ 85), mantle cell (n ¼ 69), and mature natural killer or T cell lymphoma
(n ¼ 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor
grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159
were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival
(PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P ¼ .007;
43% versus 47%; P ¼ .47; and 58% versus 60%; P ¼ .73, respectively. On multivariate analysis, a positive
pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86;
P ¼ .001) but was not associated with increased mortality (RR, 1.29, 95% conﬁdence interval [CI], .96 to 1.7;
P ¼ .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P ¼ .10), or nonrelapse mortality (RR, .75; 95% CI, .48
to 1.18; P ¼ .22). PET status conferred no inﬂuence on graft-versus-host disease. A positive PET scan before
HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful
allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION FDG-avid lymphomas or subtypes where expected FDG avidity rates ranged
Allogeneic hematopoietic cell transplantation (HCT) can
provide long-term survival for patients with various
subtypes of lymphoma; however, relapse remains the
predominant cause of treatment failure [1-4]. The use of 18F-
ﬂuorodeoxy glucose (FDG)-positron emission tomography
(PET) after front-line or salvage chemotherapy is a valuable
prognostic tool to assess the depth of remission before
autologous HCT [5-9]. FDG-PET scan metabolic positivity is
associated with a higher post-autograft relapse risk and
worse survival in patients with diffuse large B cell lymphoma
(DLBCL) and Hodgkin lymphoma (HL) [5,9]. However, it is
unclear whether FDG-PET before allogeneic HCT can be
reliably used to predict post-transplantation outcomes
among non-Hodgkin lymphoma (NHL) patients. Several
single-institution studies have found conﬂicting data on
relapse and long-term survival among allogeneic HCT
recipients according to pretransplantation PET status; how-
ever, these studies were based on smaller cohorts of patients
(58 to 88 patients) and often included patients with both HL
and NHL [10-13]. We conducted a retrospective, multicenter,
registry-based analysis of a large cohort of NHL patients to
determine whether FDG-PET performed before allogeneic
HCT can be used to predict post-transplantation outcomes.
PATIENTS AND METHODS
Data Sources
The Center of International Blood and Marrow Transplantation Registry
(CIBMTR) is a working group of more than 450 transplantation centers
worldwide that contribute detailed data on HCTs longitudinally with yearly
follow-up to a statistical center at the Medical College of Wisconsin. Centers
report HCTs consecutively, with compliance monitored by on-site audits.
The study was performed in compliance with federal regulations and the
institutional review board of the Medical College of Wisconsin.
Patients
We included adults undergoing ﬁrst allogeneic HCT for a histologically
proven diagnosis of follicular lymphoma (FL), DLBCL, mantle cell lymphoma
(MCL), or mature T cell or natural killer (NK) cell neoplasm between 2007
and 2012. Eligible histological subtypes were restricted to either routinelyfrom 80% to 100% [14,15]. Patients not responding (ie, not achieving a
complete or partial remission [CR or PR]) to the last line of therapy (n¼ 104),
with an untreated relapse (n ¼ 50) before allogeneic HCT, or undergoing
ex vivo graft manipulation (n ¼ 4) or post-transplantation cyclophospha-
mide (n¼ 1) were excluded.We identiﬁed 998 potential cases and contacted
transplantation centers for additional information about availability, date,
and status of the last FDG-PET scan performed before allogeneic HCT
(Supplemental Appendix Figure). Among the 815 (81.2%) responses
received, 367 patients met the eligibility criteria of the protocol, including
the ﬁnal designation of FDG-PET status as assessed by the local radiology
team in individual centers. Cases where the interval between the FDG-PET
scan and day 0 of allogeneic HCT was > 3 months were excluded (n ¼ 31).Deﬁnitions
The CIBMTR form deﬁnes CR after the last line of therapy before HCT as
complete resolution of all known disease on radiographic (computerized
tomography [CT] scan) assessments. PR required  50% reduction in the
greatest diameter of all sites of known disease and no new sites of disease.
Pre-HCT PET scan status determination (positive scan versus negative scan)
was performed by the reporting transplantation center according to
routinely used criteria at individual centers.
Conditioning regimens were categorized by intensity using established
consensus criteria [16]. Previously established criteria for categorizing the
degree of HLA matching were used for unrelated donor transplantations
[17]. Well-matched patients had either no identiﬁed HLA mismatching and
informative data at 4 loci or allele matching at HLA-A, -B, and -DRB1 (6/6).
Partially matched pairs had a deﬁned, single-locus mismatch, and/or
missing HLA data. Mismatched cases had  2 allele or antigen mismatches.Study Endpoints
Primary outcomes were relapse/progression and progression-free sur-
vival (PFS); secondary outcomes were nonrelapse mortality (NRM) and
overall survival (OS). NRM was deﬁned as death without evidence of lym-
phoma relapse; relapse/progression was deﬁned as progressive lymphoma
after HCT or lymphoma recurrence after a CR; NRM was considered a
competing risk. For PFS, treatment failure occurred at the time of relapse or
death from any cause. Patients alive without evidence of disease relapse
were censored at last follow-up. OSwas deﬁned as the interval from the date
of transplantation to the date of death or last follow-up. Acute graft-versus-
host disease (GVHD) was deﬁned and graded based on the pattern and
severity of organ involvement using established criteria [18]. Chronic GVHD
was deﬁned as the development of any evidence of chronic GVHD based on
clinical criteria [19].
Table 1
Patient and Disease Characteristics
Variable FDG-PET FDG-PETþ P Value
No. of patients 177 159
Age at transplantation, yr* .950
Median (range) 54 (19-71) 55 (18-70)
Karnofsky score before HCT* .054
<90% 45 (25) 48 (30)
90% 128 (72) 100 (63)
Missing 4 (2) 11 (7)
Sex* .571
Male 110 (62) 94 (59)
Female 67 (38) 65 (41)
Histology* .009
FL 44 (25) 60 (38)
DLBCLy 41 (23) 44 (28)
MCL 41 (23) 28 (18)
Mature T cell and
NK cell neoplasmz
51 (29) 27 (17)
No. of prior chemotherapy lines* .025
1-2 68 (43) 44 (30)
3 92 (58) 102 (70)
Missing 17 13
Disease status before
transplantationx
<.001
CRk 147 (83) 6 (4)k
PR 30 (17) 153 (96)
Extranodal involvement
before transplantation*
<.001
No 154 (87) 99 (62)
Yes 20 (11) 58 (36)
Unknown 3 (2) 2 (1)
Bulky disease before
transplantation (nodal)
<.001
<5 cm 8 (5) 68 (43)
5 cm 1 (1) 16 (10)
No nodal involvement
before transplantation
153 (86) 33 (21)
Missing 15 (8) 42 (26)
BM involvement before
transplantation
<.001
No 12 (7) 35 (22)
Yes 8 (5) 22 (14)
Unknown 157 (89) 102 (64)
Symptoms at diagnosis .328
A 84 (47) 72 (45)
B 59 (33) 46 (29)
Missing 34 (19) 41 (26)
Elevated LDH before
transplantation*
43 (26) 47 (33) .179
Missing 11 16
Interval from diagnosis to
transplantation (range), mo*
26 (3-208) 28 (4-352) .320
Interval from FDG-PET to
transplantation (range), mo
1 (.20-2.80) 1 (.07-2.83) .595
Prior autologous transplantation* 41 (23) 28 (18) .208
Time from autoHCT to alloHCT,
(range) mo
24 (7-133) 21 (7-66) .447
12 8 (5) 5 (3)
>12 33 (19) 23 (14)
BM indicates bone marrow; LDH, lactate dehydrogenase; auto, autologous;
allo, allogeneic.
* Variables considered in multivariate analysis.
y Thirty-two transformed patients were included (32 out of 85 DLBCL).
z FDG-PET: mycosis fungoides (n ¼ 1), anaplastic large T cell (n ¼ 12),
peripheral T cell (n ¼ 9), angioimmunoblastic T cell (n ¼ 9), adult T cell
leukemia/lymphoma (n ¼ 3), extranodal NK/T cell (n ¼ 4), other NK (n ¼ 9),
hepatosplenic gamma delta T-cell (n ¼ 2), subcutaneous panniculitis T-cell
(n ¼ 2); FDG-PETþ: peripheral T cell (n ¼ 10), angioimmunoblastic T cell
(n ¼ 7), extranodal NK/T cell (n ¼ 2), other NK cell (n ¼ 4), subcutaneous
panniculitis T cell (n ¼ 2), anaplastic large T cell (n ¼ 2).
x Disease status: FDG-PET: CR (CR1 ¼ 40 and CR2þ ¼ 107), PR (PIF
sensitive ¼ 14 and REL sensitive ¼ 16); FDG-PETþ: CR (CR1 ¼ 1 and CR2þ ¼
5), PR (primary induction failure [PIF] sensitive ¼ 54 and relapse [REL]
sensitive ¼ 99).
k FDG-PET/CT reports of 6 patients who were in CR by CT criteria but with
PETþ scans were reviewed. In all patients, CR by CT criteria was conﬁrmed.
All cases had metabolic activity in nonenlarged lymph nodes.
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Probabilities of PFS and OS were calculated using the Kaplan-Meier
estimator. Probabilities of NRM and lymphoma relapse were calculated
using cumulative incidence curves to account for competing risks. Patient-,
disease-, and transplantation-related factors were compared between PET-
positive and PET-negative groups using the chi-square test for categorical
variables and the Wilcoxon sample test for continuous variables. Associa-
tions among patient-, disease-, and transplantation-related variables and
outcomes of interest were evaluated using multivariate Cox proportional
hazards regression. A stepwise selection multivariate model was built to
identify covariates that inﬂuenced outcomes. Covariates with a P < .05 were
considered signiﬁcant. The proportionality assumption for Cox regression
was tested by adding a time-dependent covariate for each risk factor and
each outcome. Covariates violating the proportional hazards assumption
were stratiﬁed in the Cox regression model. Results are expressed as relative
risk (RR) or the relative rate of occurrence of the event.
Variables considered in multivariate analysis included positive or
negative PET status (the main effect) and clinical factors listed in Tables 1
and 2 (denoted by an asterisk sign). Potential interactions among the
main effect and all signiﬁcant covariates were tested. CR versus PR and
bulky disease (5 cm) at HCT were not included in multivariate analysis
owing to the strong correlation of CR with PET-negative status and
presence of bulky disease with PET-positive status.
RESULTS
Patients Characteristics
We examined data on 336 eligible patients from 81
reporting centers (Tables 1 and 2). Median age was 55 years
(range, 18 to 71); 60% were males. FL (n ¼ 104) was more
common than DLBCL (n ¼ 85), MCL (n ¼ 69), and mature NK
or T cell (n ¼ 78) lymphomas. Patients underwent FDG-PET
scanning a median of 1 month (range, .07 to 2.83 months)
before allografting; 159 were FDG-PET positive (FDG-PETþ)
and 177 FDG-PET negative (FDG-PET). As expected, there
were differences in disease characteristics between FDG-
PETþ and FDG-PET groups (Table 1). FDG-PETþ patients
more often had FL (38% versus 25%), 3 lines of prior therapy
(70% versus 58%), extranodal disease before HCT (36% versus
11%), marrow involvement before HCT (14% versus 5%), and
bulky disease before HCT (10% versus 1%) compared with the
FDG-PET cohort. Pretransplantation radiation was admin-
istered for 20% of FDG-PETþ patients and 24% of FDG-PET
patients before PET imaging. The interval from diagnosis to
transplantation was similar (median 28 versus 26 months).
In addition, similar proportions of patients in both groups
received rituximab-containing conditioning (25% versus
19%) and peritransplantation antithymocyte globulin/alem-
tuzumab (26% versus 27%), and only a few had radiation (2%
versus 1%) after transplantation (Table 2). For the entire
cohort, most patients received reduced-intensity (RIC) or
nonmyeloablative conditioning. Less than 25% had a prior
autologous HCT, with DLBCL being the most common his-
tology (undergoing an autologous transplantation previ-
ously) in both PET groups (FDG-PETþ 46% and FDG-PET
37%; P ¼ .44) and similar distribution of other histologies.
There was no signiﬁcant difference between the FDG-PETþ
and FDG-PET cohorts in graft and donor type (Table 2).
Median follow-up of survivors was 48 months (12 to 82
months; PETþ group) and 49months (range, 3 to 75 months;
PET group).
NRM and GVHD
The cumulative incidence of NRM at 1 year was 14% (95%
conﬁdence interval [CI], 9% to 20%] in FDG-PETþ and 19%
(95% CI, 13% to 25%; P ¼ .23) in FDG-PET groups (Table 3,
Figure 1A). The respective ﬁgures at 3 years were 17% versus
27% (P ¼ .03). On multivariate analysis, FDG-PET status was
not predictive of NRM risk (Table 4). Unrelated donor
(RR, 3.59; 95% CI, 1.96 to 6.58; P < .0001) and cord blood
Table 2
Transplantation and Treatment Characteristics
Variable FDG-PET FDG-PETþ P Value
No. of patients 177 159
Donor type* .402
Cord blood 27 (15) 26 (16)
HLA-identical siblings 65 (37) 57 (36)
Unrelated well matched 59 (33) 57 (36)
Unrelated partially matched 17 (10) 17 (11)
Unrelated matching missing 9 (5) 2 (1)
Graft type* .331
Bone marrow 7 (4) 12 (8)
Peripheral blood 143 (81) 121 (76)
Cord blood 27 (15) 26 (16)
Conditioning intensity* .814
Myeloablative 50 (28) 40 (25)
Cyclophosphamide þ TBI 30 (17) 19 (12)
Busulfan þ ﬂudarabine 10 (6) 7 (4)
Other/busulfan þ
cyclophosphamide
5/4 (4/2) 6/8 (4/5)
Reduced intensity 70 (40) 66 (42)
TBI þ other 14 (9) 5 (4)
Fludarabine þ melphalan 18 (10) 21 (13)
Melphalan  othersy 16 (9) 9 (6)
Busulfan þ others 20 (12) 27 (17)
Nonmyeloablative 57 (32) 53 (33)
Fludarabine þ
cyclophosphamide þ TBI
17 (10) 20 (13)
Fludarabine þ
cyclophosphamide or TBI
37 (21) 33 (20)
Radiation  ATG 6 (3) 2 (1)
Radiation before HCT* .094
No 134 (76) 127 (80)
Yes 43 (24) 32 (20)
Rituximab at conditioning* .189
Yes 34 (19) 40 (25)
No 143 (81) 119 (75)
Donor-recipient CMV status* .336
Positive donor 25 (14) 17 (11)
Positive recipient 88 (49) 81 (51)
Donor-recipient negative 42 (24) 40 (25)
Missing 22 (12) 21 (13)
Year of transplantation .125
2007-2008 84 (47) 66 (42)
2009-2010 57 (32) 68 (43)
2011-2012 36 (20) 25 (16)
ATG/alemtuzumab* .434
ATG alone 36 (20) 30 (19)
Alemtuzumab alone 12 (7) 11 (7)
GVHD prophylaxis* .325
Tacrolimus þ MMF  others 48 (27) 29 (18)
Tacrolimus þ MTX  others
(except MMF)
58 (33) 66 (42)
Tacrolimus þ others
(except MTX, MMF)
12 (7) 17 (10)
CSA þ MMF  others
(except tacro)
31 (18) 24 (15)
CSA þ MTX  others
(except tacro, MMF)
9 (5) 10 (6)
CSA þ others
(except tacro, MTX, MMF)
5 (3) 3 (2)
Other GVHD prophylaxisz 14 (8) 10 (6)
Planned post-transplantation
radiation
1 (1) 3 (2)
Median follow-up of survivors, mo 49 (3-75) 48 (12-82)
TBI indicates total body irradiation; ATG, antithymocyte globulin; CMV,
cytomegalovirus; MMF, mycophenolate mofetil; CsA, cyclosporine; MTX,
methotrexate.
Data presented are n (%), unless otherwise indicated.
* Variables considered in multivariate analysis.
y Negative PET: Ara-C þ VP16 þ melphalanþnitro (n ¼ 9), melphalan
alone (n ¼ 2); Positive PET: Ara-C þ VP16 þ melphalan þ nitro (n ¼ 5),
Ara-C þ VP16 þ melphalan þ nitro þ Velcade (n ¼ 2), melphalan alone
(n ¼ 1), melphalan þ clorabine (n ¼ 1).
z MTX þMMF ¼ 1, KGF þMTX ¼ 1, MAB þMMF þ Campath ¼ 2, MTX þ
Siro ¼ 1, not speciﬁed ¼ 19.
Table 3
Univariate Analysis*
Outcomes FDG-PET FDG-PETþ P Value
Cumulative Incidence (CI)
Acute GVHD (grade II-IV)
100 Days 26 (20-33) 27 (21-34) .874
Chronic GVHD
1 Year 43 (36-51) 43 (36-51) .997
3 Years 52 (44-59) 54 (46-62) .717
NRM
1 Year 19 (13-25) 14 (9-20) .236
3 Years 27 (20-34) 17 (11-23) .031
Relapse/progression
1 Year 17 (12-23) 32 (25-40) .002
3 Years 26 (19-33) 40 (32-48) .007
PFS
1 Year 64 (57-71) 54 (46-62) .064
3 Years 47 (40-55) 43 (36-51) .472
OS
1 Year 75 (68-81) 72 (65-79) .581
3 Years 60 (52-67) 58 (50-65) .731
Bold P-values are statistically signiﬁcant.
* Probabilities of acute GVHD, chronic GVHD, treatment-related mortal-
ity, and relapse were calculated using the cumulative incidence estimate.
PFS and OSwere calculated using the Kaplan-Meier product limit estimate. P
values reﬂect point-wise comparison at deﬁned times.
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with increased NRM risk (Table 4). The cumulative in-
cidences of grade II to IV acute GVHD at day 100 (26% and
27%) and chronic GVHD at 1 year (43% versus 43%) were not
signiﬁcantly different between the 2 cohorts (Table 3).Relapse/Progression
The cumulative incidence of relapse at 1 year of PETþ
patients was higher than that of the PET group (32% versus
17%; P ¼ .002) (Table 3) and the relapse difference persisted
at 3 years (40% versus 26%; P ¼ .007) (Figure 1B). On multi-
variate analysis, a positive pretransplantation PET scan was
associated with increased the risk of relapse by almost 2-fold
(RR, 1.86; 95% CI, 1.26 to 2.74; P ¼ .002) (Table 4). Whereas
higher relapse risk with PETþ status was seen in all histo-
logical subtypes (3-year cumulative incidence rates: DLBCL,
51% versus 34%; P ¼ .10; MCL, 54% versus 27%, P ¼ .025; NK/T
lymphoma, 44% versus 24%; P ¼ .07); the trend was negli-
gible in patients with FL (22% versus 17%, P ¼ .50). Other
clinical factors independently prognostic of relapse risk were
lymphoma histology other than FL (RR, 1.88 to 2.36 for
different subsets) and prior autologous transplantation (RR,
1.73; P ¼ .01) and use of bone marrow grafts (RR, 3.0)
(Table 4). The median time to relapse in PET and PETþ
groups were 10 months (range, 1 to 50) and 4months (range,
.1 to 51), respectively.PFS and OS
At a median follow-up of 4 years (range, .25 to 6.8), FDG-
PET status before allograft did not affect survival. Three-year
PFS and OS for PETþ and PET groups were similar at 43%
(95% CI, 36% to 51%) versus 47% (95% CI, 40% to 55%); P ¼ .47
and 58% (50% to 65%) versus 60%; (95% CI, 52% to 67%); P ¼
.73, respectively (Figure 1C,D). Onmultivariate analysis, FDG-
PETþ status was not associated with increased risk of ther-
apy failure (ie, inferior PFS; RR, 1.29; 95% CI, .96 to 1.74; P ¼
.08) or mortality (ie, inferior OS; RR, 1.32; 95% CI, .94 to 1.84;
P ¼ .10). Factors signiﬁcantly associated with therapy failure
Figure 1. Cumulative incidence of NRM (A) and relapse (B) and Kaplan-Meyer estimates of PFS (C) and OS (D).
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mortality (donor type, stem cell source, lymphoma sub-
group, and conditioning intensity) are summarized in
Table 4.
Causes of Death
In the FDG-PETþ group, 75 patients died. The most
common causes of death were primary disease (55%) fol-
lowed by GVHD (19%), organ failure (8%), and infection (8%).
FDG-PET patients (n ¼ 73) died most often of primary
disease (36%), GVHD (25%), organ failure (18%), and in-
fections (8%) (Table 5).
DISCUSSION
In our multicenter retrospective analysis of 336 patients,
the largest cohort studied for the association between FDG-
PET status and allogeneic HCT outcomes to our knowledge,
we found that patients with residual lymphoma, as detected
by FDG uptake on PET imaging, had amodestly increased risk
of disease relapse after transplantation. Long-term survival,
however, was similar for all lymphoma patients receiving
allogeneic HCT in our cohort regardless of PET status.
Our results showed a link between a positive FDG-PET
scan and clinical factors before transplantation, including
extranodal involvement, presence of bulky disease, marrow
involvement, and more prior lines of therapy, suggesting
biologic differences in the compared PET status groups.
Whereas 3-year NRM appeared to be higher in PET patients
compared with PETþ patients on univariate analysis, the
difference, which is partially attributable to competing risk of
early progressive disease in PETþ patients, was not
conﬁrmed after adjusting for potential confounding factors
in multivariate analysis. It is important to highlight that all
patients included in the current study were chemosensitive
by CT criteria and, regardless of metabolic depth of remission
immediately before transplantation, allogeneic HCT yielded
3-year survival close to 60%. Our results suggest that in NHL
patients demonstrating chemosensitive disease by conven-
tional radiographic criteria, a FDG-PET (at least as clinicallyapplied in individual centers across the world) is not pre-
dictive of post-allogeneic HCT survival outcomes. Disease
control long-term beneﬁts from graft-versus-lymphoma
(GVL) responses and the availability of effective salvage
therapies in the case of post-allogeneic HCT relapse of NHL.
The GVL effect in our series is further implied by improved
survival using peripheral blood compared with marrow graft
source.
We recognize that variations in PET techniques and
interpretation among centers in different countries exist and
evolve over time. In general, PET/CT interpretation guidelines
from the International Harmonization Project in Lymphoma
recommend using visual assessment of residual mass (posi-
tive versus negative) with mediastinal blood pool activity or
background activity as the reference [20]. We collected
additional supplemental data from centers and utilized the
pre-HCT PET status as determined by the reporting trans-
plantation center using their institutional practice and
criteria. This strategy allowed us to examine the utility of
pre-allograft PET scan, as practiced and utilized in the “real-
world.” Whether our observations would be applicable to
PET images interpreted centrally or by using standardized 5-
point scale criteria is not known and likely beyond the scope
of a registry analysis [20,21]. This limitation highlights the
future need to use standardized 3- or 5-point scale PET im-
aging in forthcoming studies [14]. It is also important to
highpoint that the Deauville criteria were published in late
2009 and nearly one half of the subjects included in our
analysis underwent transplantation before the availability of
these guidelines. Until future prospective studies are con-
ducted in NHL histological subsets using standardized PET
imaging methods, our analysis provides clinically relevant
insights on the predictive value of PET after allograft for
patients with NHL.
Current published data contain limited and contrasting
ﬁndings on the predictive value of FDG-PET imaging. Dodero
et al. reviewed 80 patients (34 with high-grade NHL and 46
with HL) before RIC allogeneic HCT [10]. PET positivity pre-
dicted survival, but over one half of the patients had HL, a
Table 4
Multivariate Analysis
Factor N RR (95% CI) P Value
NRM
Main effect
FDG-PET 177 1
FDG-PETþ 156 .754 (.479-1.185) .2202
Donor type
HLA-identical sibling 120 1
Cord blood 53 2.691 (1.2-6.032) .0162
Unrelated 160 3.595 (1.964-6.583) <.0001
Stem cell source
Bone marrow 18 1
Peripheral blood 262 .33 (.16-.67) .0025
Relapse/progression
Main effect
FDG-PET 177 1
FDG-PETþ 156 1.862 (1.263-2.745) .0017
Histology
FL 104 1
DLBCL 82 2.365 (1.378-4.059) .0018
MCL 69 2.122 (1.209-3.726) .0088
T and NK neoplasm 78 1.882 (1.051-3.369) .0333
Prior auto transplantation
Yes 66 1
No 267 .578 (.38-.881) .0109
Therapy failure (inverse of PFS)
Main effect
FDG-PET 177 1
FDG-PETþ 156 1.297 (.966-1.741) .0833
Donor type
HLA-identical sibling 120 1
Cord blood 53 1.896 (1.228-2.929) .0039
Unrelated 160 1.521 (1.083-2.136) .0155
Stem cell source
Bone marrow 18 1
Peripheral blood 262 .54 (.3-.5) .03
Histology
FL 104 1
DLBCL 82 2.094 (1.401-3.131) .0003
MCL 69 1.873 (1.23-2.853) .0035
T and NK neoplasm 78 1.548 (.995-2.408) .0527
Mortality (OS)
Main effect
FDG-PET 177 1
FDG-PETþ 159 1.321 (.946-1.844) .1028
Donor type
HLA-identical sibling 122 1
Cord blood 53 2.098 (1.266-3.476) .004
Unrelated 161 2.064 (1.379-3.09) .0004
Stem cell source
Bone marrow 18 1
Peripheral blood 262 .38 (.21-.67) .0008
Histology
FL 104 1
DLBCL 85 2.393 (1.489-3.846) .0003
MCL 69 1.844 (1.118-3.041) .0166
T and NK neoplasm 78 1.706 (1.01-2.883) .0458
Conditioning regimen
Myeloablative 90 1
Table 5
Causes of Death
Cause of Death FDG-PET FDG-PETþ
Total no. of deaths 73 75
Primary disease 26 (36) 41 (55)
Infection 6 (8) 6 (8)
Idiopathic pneumonia syndrome 0 3 (4)
GVHD 17 (23) 14 (19)
Organ failure 13 (18) 6 (8)
Second malignancy 3 (4) 3 (4)
Hemorrhage 0 1 (1)
Severe platelet transfusion reaction 1 (1) 0
Not speciﬁed 7 (10) 1 (1)
Data presented are n (%).
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of chemosensitivity and possibly weaker GVL effects [22,23].
Our cohort appears more homogenous, as HL patients were
not included. A study from the University College London
that reported outcomes of 88 patients with predominantly
indolent NHL treated with alemtuzumab-containing RIC
conditioning and risk-adapted post-HCT donor lymphocyte
infusion showed a lack of difference in relapse and similar
PFS between PETþ patients versus PET groups; however,
persistence of PET activity after transplantation most often
predicted imminent relapse and reduced PFS [11-13]. More
recent single-institution studies from the University ofMinnesota and Memorial Sloan Kettering used Deauville
score PET interpretation in their cohorts (78 and 58 NHL
allograft recipients, respectively) who were chemosensitive
by CT criteria and found no difference in event-free survival
or OS between FDG-PET positive (Deauville 4, 5) and FDG-
PET negative (Deauville 1 to 3) patients [12,13]. It is impor-
tant to highlight that most aforementioned series studying
PET in allogeneic HCT, including ours, comprised predomi-
nantly indolent NHL histologies, whereas publication on
autologous HCT [5,8,9] included predominantly aggressive
histologies. Biologic differences inherent to histologic sub-
types clearly impact on predictive utility of PET; however,
more data will be needed to assess implications of pre-
transplantation functional imaging in speciﬁc histologic
subsets.
Our results provide potentially useful clinical information
for interpreting the prognostic meaning of FDG-PET imaging
results in the setting of allogeneic HCT. For example, whereas
PET negativity leads to a lower risk of relapse, PET positivity
may guide decisions about post-transplantation in-
terventions to reduce relapse. Importantly, a positive PET
scan should not be interpreted as a barrier to a successful
allograft. It is a potentially modiﬁable variable affecting early
relapse and, unlike histology or prior autograft, can be
targeted by pre- or peritransplantation strategies [24,25].
Our study also highlights the need to standardize interpre-
tation of PET scans and examine the utility of the Deauville
scoring system in NHL and within the context of allogeneic
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